Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 3/20 | 0.50 |
| ▸ | GABRD | O14764 | 3/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.50 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.50 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.50 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.50 |
| ▸ | GABRE | P78334 | 3/20 | 0.50 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.50 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.50 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.50 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL631872 | 0.98 | GABRP (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30664846 | 0.83 | IKBKB (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL392559 | 0.83 | IKBKB (0.46) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL920297 | 0.83 | GABRP (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31139883 | 0.82 | GABRP (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20657822 | 0.82 | GABRP (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL921022 | 0.81 | GABRP (0.62) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Lithium Ion SCHEMBL631871 | 0.80 | KDM4E (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL56617 | 0.78 | SMN1; SMN2 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29378242 | 0.78 | SMN1; SMN2 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 351 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119841817-B | Aromatic ester compound containing benzo five-membered ring, and preparation method and application thereof | 山东省联合农药工业有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250382288-A1 | 8-AZA QUINAZOLINES AS BRAIN-PENETRANT SOS1-INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2025-12-18 | — | — | US | disclosed |
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250282776-A1 | Bicyclic TLR7 Agonists and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4574816-A1 | HETEROCYCLIC COMPOUND CAPABLE OF INHIBITING PRMT5 - MTA AND USE THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2025-06-25 | — | — | EP | disclosed |
| CN-116265462-B | Heterocyclic compound with antitumor activity and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119841817-A | Aromatic ester compound containing benzo five-membered ring, and preparation method and application thereof | 山东省联合农药工业有限公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2025067457-A1 | HETEROCYCLIC FUSED RING COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119546582-A | Heterocyclic compound capable of inhibiting PRMT5.MTA and application thereof | 西藏海思科制药有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20250051330-A1 | HETEROCYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2025-02-13 | — | — | US | disclosed |
| US-20070082913-A1 | Substituted heterocyclic compounds with CXCR3 antagonist activity | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| EP-1771420-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | BARTKOVITZ DAVID J | 2006-01-19 | — | — | US | disclosed |
| WO-2006005548-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082913-A1 | Substituted heterocyclic compounds with CXCR3 antagonist activity | CXCR3, CXCL10, CXCR1 | GABRP 3251/4885GABRD 2784/4885GABRA1 2572/4885 |
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | GABRP 3663/4885GABRD 4139/4885GABRA1 3929/4885 |
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN2, SNRPA1 | GABRP 1661/4885GABRD 1546/4885GABRA1 2363/4885 |
| US-20250282776-A1 | Bicyclic TLR7 Agonists and Uses Thereof | TLR7, TLR9, TLR1 | GABRP 652/4885GABRD 795/4885GABRA1 473/4885 |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | CDK2, CCNA2, CDK6 | GABRP 4595/4885GABRD 3908/4885GABRA1 4738/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | GABRP 3663/4885GABRD 4139/4885GABRA1 3929/4885 |
| US-20250382288-A1 | 8-AZA QUINAZOLINES AS BRAIN-PENETRANT SOS1-INHIBITORS | SOS1, SOS2, SOST | GABRP 3559/4885GABRD 3250/4885GABRA1 1692/4885 |
| US-20250051330-A1 | HETEROCYCLIC COMPOUND HAVING ANTI-TUMOR ACTIVITY AND USE THEREOF | SOS1, HINT1, WNT1 | GABRP 3951/4885GABRD 4063/4885GABRA1 2463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.